Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Arch. méd. Camaguey ; 24(4): e7261, jul.-ago. 2020. tab
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1131143

RESUMO

RESUMEN Fundamento: la degeneración macular relacionada con la edad está entre las causas más comunes de pérdida visual severa e irreversible en pacientes mayores de 60 años en el mundo industrializado. Es considerado el aumento de la esperanza de vida en la población de los adultos mayores, la necesidad de un diagnóstico temprano y oportuno, es obvio para esta enfermedad que constituye un problema de salud a resolver. Objetivo: describir los resultados de la cicatrización con el uso del bevacizumab en la degeneración macular relacionada con la edad húmeda. Métodos: se realizó un estudio descriptivo, longitudinal en pacientes con el diagnóstico de degeneración macular relacionada con la edad húmeda. La población la conformaron 25 pacientes que acudieron a la consulta de retina en el periodo de octubre 2018 a abril 2019 y que cumplieron con los criterios de selección. Se les aplicó una encuesta y se estudiaron variables como: edad, sexo, antecedentes patológicos personales, número de inyecciones intravitreas colocadas a cada paciente, complicaciones post inyección y cicatrización de la lesión macular. BMMEM Resultados: según el comportamiento de los grupos de edades y el sexo, se encontró que la edad entre 60 y 69 fue de diez pacientes y el sexo femenino 15 pacientes fueron los más frecuentes. La hipertensión ocular fue la complicación que predominó. El antecedente patológico personal más frecuente fue la hipertensión arterial con cuatro pacientes. La mayor cantidad de ojos cicatrizaron con la administración de una y dos dosis del medicamento. Conclusiones: predominó el grupo de edad de 60 a 69 años y el sexo femenino. La hipertensión ocular fue la complicación más frecuente. Se constató la hipertensión arterial como el antecedente patológico personal más habitual. La cicatrización de los ojos ocurrió con la administración entre una y dos dosis.


ABSTRACT Background: the age-related macular degeneration is among the most common causes of harsh and irreversible visual loss in patient elders of 60 years in the industrialized world. Considering the increase of life expectancy and the rise in population of the senior citizens, the need of an early and opportune diagnosis, it is obvious for this disease that constitutes a health problem we have to solve. Objective: to describe the results of the cicatrization with the use of the bevacizumab in the age-related humid macular degeneration. Methods: a descriptive, longitudinal study in patients with the diagnosis of age-related humid macular degeneration was carried out. 25 patients that attended the retinal consultation in the period October, 2018 to April, 2019 and who fulfilled the criteria constituted the population of selection. They were applied an opinion poll and they studied variables were: Age, sex, pathological personal background, number of intravitreous injections placed to each patient, complications after injection and cicatrization of the macular injury. B Results: according to the age groups and the sex, it was shown that the age between 60 and 69, ten patients and the feminine sex 15 patients were the most frequent. The ocular hypertension was the complication that predominated with four patients. The greatest amount of eyes healed with the administration of one and two doses of the medication. Conclusions: the age group from 60 to 69 years and the feminine sex predominated. The ocular hypertension was the most frequent complication. It was verified high blood pressure as the most frequent pathological antecedent. The cicatrization of the eyes happened with the administration between one and two doses.

2.
Rev. bras. ginecol. obstet ; Rev. bras. ginecol. obstet;40(11): 664-672, Nov. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-977800

RESUMO

Abstract Objective To compare two different treatments—the use of highly purified anhydrous (HPA) lanolin and expressed breast milk—for women with pain and nipple trauma during the breastfeeding process. Method A total of 180 puerperal women were randomly assigned to 2 groups: one was treated with HPA lanolin and the other with their own expressed breast milk. All of the participants received the same breastfeeding technique instructions and therapeutic care standard. Three assessments were performed: at the time of inclusion in the study (after randomization); after 48 hours; and after 7 days. At each interval, data was collected in relation to pain and trauma. A numerical/verbal category scale was used for the pain variable, and the nipple trauma score for the trauma variable. The results were subjected to statistical analysis using the chi-squared test, the Fisher exact test, the student t-test, and the Kolmogorov-Smirnov test. Generalized estimating equations were calculated using the STATA 12 statistical software package (StataCorp LLC, College Station, TX, USA) and IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp, Armonk, NY, USA). Results There was pain improvement from the second to the third assessment in the group that used HPA lanolin, while the pain remained unchanged between these two periods (p< 0.001) in the breast milk group. In terms of trauma, improvement was identified in its extension and depth from the first to the third assessment, and it was higher in the HPA lanolin group than in the breast milk group (p= 0.025). Conclusion The treatment of pain and nipple trauma with HPA lanolin achieved better results than the one with breast milk, based on a 7-day treatment period.


Resumo Objetivo Comparar dois tratamentos distintos—o uso de lanolina anidra altamente purificada (HPA, na sigla em inglês) e o próprio leite materno—para mulheres com dor e trauma mamilar durante o processo de amamentação. Métodos Participaram do estudo 180 puérperas randomizadas para 2 grupos: um utilizou tratamento com lanolina HPA e o outro o próprio leite materno. Todas receberam a mesma orientação quanto à técnica de amamentação e rigor terapêutico e foram avaliadas em três momentos: na inclusão no estudo (após a randomização), em 48 horas e em 7 dias. Em todos os momentos, foram colhidos dados em relação à dor e ao trauma. Para a variável dor, utilizou-se escala de categoria numérica/nerbal e, para a variável trauma, a pontuação de traumas mamilares. Os testes estatísticos utilizados foram: Qui-quadrado, teste exato de Fisher, t de Student, e Kolmogorov-Smirnov, sendo que os modelos de equações de estimação generalizadas foram calculados por meio dos pacotes STATA 12 (StataCorp LLC, College Station, TX, EUA) e IBM SPSS Statistics for Windows, Versão 20.0 (IBM Corp, Armonk, NY, EUA). Resultados Houve melhora da dor da segunda para a terceira avaliação no grupo que utilizou a lanolina HPA, enquanto que no grupo que usou leite materno a dor permaneceu inalterada entre esses dois momentos (p< 0,001). Quanto ao trauma, foi identificada melhora em sua extensão e profundidade, da primeira para a terceira avaliação, e a melhora foi maior no grupo tratado com lanolina HPA do que no grupo tratado com leite materno (p= 0,025). Conclusão O tratamento da dor e do trauma mamilar com lanolina HPA teve melhor resultado comparado com o leite materno, com base em um período de tratamento de 7 dias.


Assuntos
Humanos , Feminino , Adolescente , Adulto , Adulto Jovem , Manejo da Dor/métodos , Lanolina/uso terapêutico , Leite Humano , Mamilos/lesões , Dor/etiologia , Aleitamento Materno/efeitos adversos , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA